Optical and multimodal peptide-based probes for in vivo molecular imaging

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 476-499

  Melendez Alafort, Laura ^a   Muzzio, Pier Carlo ^a,b   Rosato, Antonio ^a,b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cancer Imaging; In Vivo Molecular Imaging; Liposomes; MRI Imaging; Multimodal Probes; Multimodal Targeting; Nanoparticles; Nanotubes; Optical imaging; Peptide Hormones; Peptide PET Imaging; Photoacoustic imaging; Quantum Dots; Radionuclide Imaging; Raman Imaging; SPECT Imaging; Tumor Targeting

Indexed keywords

ANGIOPEPTIN; BROMINE 76; CARBON; CARBON 11; CARBOXYFLUORESCEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CHELATING AGENT; COPPER 64; CYANINE DYE; EXENDIN 4; FLUORESCEIN ISOTHIOCYANATE; FLUORINE 18; GALLIUM 67; GALLIUM 68; INDIUM 111; INDOCYANINE GREEN; IODINE 123; IODINE 124; KNOTTIN; METAL COMPLEX; NEAR IR CF; NITROGEN 13; OCTREOTIDE; OXYGEN 15; PEPTIDE; RADIOISOTOPE; SAMARIUM 153; TECHNETIUM 99M; THALLIUM 201; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOCHEMISTRY; BIOLUMINESCENCE; BLEACHING; CYCLOTRON; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG HALF LIFE; FLUORESCENCE IMAGING; FLUORESCENCE MOLECULAR TOMOGRAPHY; FLUORESCENCE REFLECTANCE IMAGING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; IMAGE QUALITY; IN VIVO STUDY; ISOTOPE LABELING; LABELING INDEX; LIGHT ABSORPTION; MOLECULAR IMAGING; NEAR INFRARED REFLECTANCE SPECTROSCOPY; NEAR INFRARED SPECTROSCOPY; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; OPTICAL IMAGING; OPTICAL TOMOGRAPHY; PHOTOACOUSTICS; PHOTON; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIVITY; REVIEW; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; X RAY;

EID: 84861661526     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617858     Document Type: Review

References (282)

1. Hoffman, J. M.; Gambhir, S. S. Molecular imaging: The vision and opportunity for radiology in the future. Radiology, 2007, 244 (1), 39-47.
2. Weissleder, R.; Mahmood, U. Molecular imaging. Radiology, 2001, 219 (2), 316-333.
3. Cai, W. B.; Rao, J. H.; Gambhir, S. S.; Chen, X. Y. How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther., 2006, 5 (11), 2624-2633.
4. Reubi, J. C.; Maecke, H. R. Peptide-based probes for cancer imaging. J. Nucl. Med., 2008, 49 (11), 1735-1738.
5. Lee, S.; Xie, J.; Chen, X. Y. Peptide-based probes for targeted molecular imaging. Biochemistry, 2010, 49 (7), 1364-1376.
6. Lopez-Barcons, L. A.; Ali, A. N.; Diaz, R. Application of recombinant and non-recombinant peptides in the determination of tumor response to cancer therapy. Current Pharmaceutical Biotechnology, 2011, 12 (2), 320-335.
7. Chen, K.; Chen, X. Y. Design and development of molecular imaging probes. Curr. Top. Med. Chem., 2010, 10 (12), 1227-1236.
8. Reubi, J. C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30 (5), 781-793.
9. Lee, S.; Xie, J.; Chen, X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev, 2010, 110 (5), 3087-111.
10. de Visser, M.; Verwijnen, S. M.; de Jong, M. Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother. Radiopharm., 2008, 23 (2), 137-157.
11. Ferro-Flores, G.; de Murphy, C. A.; Melendez-Alafort, L. Third generation radiopharmaceuticals for imaging and targeted therapy. Curr. Pharm. Anal., 2006, 2 (4), 339-352.
12. Sandanaraj, B. S.; Kneuer, R.; Beckmann, N. Optical and magnetic resonance imaging as complementary modalities in drug discovery. Future Medicinal Chemistry, 2010, 2 (3), 317-337.
13. Massoud, T. F.; Gambhir, S. S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev., 2003, 17 (5), 545-580.
14. Ferro-Flores, G.; Ramirez, F. D.; Melendez-Alafort, L.; Santos-Cuevas, C. L. Peptides for in vivo target-specific cancer imaging. Mini-Reviews in Medicinal Chemistry, 2010, 10 (1), 87-97.
15. Anderson, C. J.; Ferdani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother. Radiopharm., 2009, 24 (4), 379-393.
16. Chen, K.; Conti, P. S. Target-specific delivery of peptide-based probes for PET imaging. Advanced Drug Delivery Reviews, 2010, 62 (11), 1005-1022.
17. Spanoudaki, V. C.; Ziegler, S. I. PET & SPECT instrumentation. Handb Exp Pharmacol, 2008, (185 Pt 1), 53-74.
18. Pimlott, S. L.; Sutherland, A. Molecular tracers for the PET and SPECT imaging of disease. Chem. Soc. Rev., 2011, 40 (1), 149-162.
19. Sosabowski, J.; Melendez-Alafort, L.; Mather, S. Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases. Quarterly Journal of Nuclear Medicine, 2003, 47 (4), 223-237.
20. Hartwell, L.; Mankoff, D.; Paulovich, A.; Ramsey, S.; Swisher, E. Cancer biomarkers: a systems approach. Nature Biotechnology, 2006, 24 (8), 905-908.
21. George, A. J. T.; Bhakoo, K. K.; Haskard, D. O.; Larkman, D. J.; Reynolds, P. R. Imaging molecular and cellular events in transplantation. Transplantation, 2006, 82 (9), 1124-1129.
22. Meikle, S. R.; Kench, P.; Kassiou, M.; Banati, R. B. Small animal SPECT and its place in the matrix of molecular imaging technologies. Phys. Med. Biol., 2005, 50 (22), R45-R61.
23. Schottelius, M.; Wester, H. J. Molecular imaging targeting peptide receptors. Methods, 2009, 48 (2), 161-177.
24. Mather, S. Molecular imaging with bioconjugates in mouse models of cancer. Bioconjug Chem, 2009, 20 (4), 631-43.
25. Sato, A.; Klaunberg, B.; Tolwani, R. In vivo bioluminescence imaging. Comparative Medicine, 2004, 54 (6), 631-634.
26. Becker, A.; Hessenius, C.; Licha, K.; Ebert, B.; Sukowski, U.; Semmler, W.; Wiedenmann, B.; Grotzinger, C. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nature Biotechnology, 2001, 19 (4), 327-331.
27. Ntziachristos, V.; Ripoll, J.; Weissleder, R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Optics Letters, 2002, 27 (5), 333-335.
28. Rudin, M.; Weissleder, R. Molecular imaging in drug discovery and development. Nature Reviews Drug Discovery, 2003, 2 (2), 123-131.
29. Achilefu, S. Lighting up tumors with receptor-specific optical molecular probes. Technology in Cancer Research & Treatment, 2004, 3 (4), 393-409.
30. Weissleder, R. A clearer vision for in vivo imaging. Nature Biotechnology, 2001, 19 (4), 316-317.
31. Klohs, J.; Steinbrink, J.; Nierhaus, T.; Bourayou, R.; Lindauer, U.; Bahmani, P.; Dirnagl, U.; Wunder, A. Noninvasive near-infrared imaging of fluorochromes within the brains of live mice: An in vivo phantom study. Molecular Imaging, 2006, 5 (3), 180-187.
32. Tung, C. H.; Quinti, L.; Jaffer, F. A.; Weissleder, R. A branched fluorescent peptide probe for imaging of activated platelets. Molecular Pharmaceutics, 2005, 2 (1), 92-95.
33. Gremlich, H. U.; Martínez, V.; Kneuer, R.; Kinzy, W.; Weber, E.; Pfannkuche, H. J.; Rudin, M. Noninvasive assessment of gastric emptying by near-infrared fluorescence reflectance imaging in mice: pharmacological validation with tegaserod, cisapride, and clonidine. Mol Imaging, 2004, 3 (4), 303-11.
34. Graves, E. E.; Culver, J. P.; Ripoll, J.; Weissleder, R.; Ntziachristos, V. Singular-value analysis and optimization of experimental parameters in fluorescence molecular tomography. Journal of the Optical Society of America a-Optics Image Science and Vision, 2004, 21 (2), 231-241.
35. Gao, M.; Lewis, G.; Turner, G. M.; Soubret, A.; Ntziachristos, V. Effects of background fluorescence in fluorescence molecular tomography. Applied Optics, 2005, 44 (26), 5468-5474.
36. Graves, E. E.; Ripoll, J.; Weissleder, R.; Ntziachristos, V. A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Medical Physics, 2003, 30 (5), 901-911.
37. Graves, E. E.; Weissleder, R.; Ntziachristos, V. Fluorescence molecular imaging of small animal tumor models. Current Molecular Medicine, 2004, 4 (4), 419-430.
38. Ntziachristos, V.; Schellenberger, E. A.; Ripoll, J.; Yessayan, D.; Graves, E.; Bogdanov, A.; Josephson, L.; Weissleder, R. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101 (33), 12294-12299.
39. Ntziachristos, V.; Weissleder, R. Charge-coupled-device based scanner for tomography of fluorescent near-infrared probes in turbid media. Medical Physics, 2002, 29 (5), 803-809.
40. Dutta, J.; Ahn, S.; Joshi, A. A.; Leahy, R. M. Illumination pattern optimization for fluorescence tomography: theory and simulation studies. Phys. Med. Biol., 2010, 55 (10), 2961-2982.
41. Han, D.; Yang, X.; Liu, K.; Qin, C. H.; Zhang, B.; Ma, X. B.; Tian, J. Efficient reconstruction method for L1 regularization in fluorescence molecular tomography. Applied Optics, 2010, 49 (36), 6930-6937.
42. Lyons, A. B.; Parish, C. R. Determination of lymphocyte division by flow-cytometry J. Immunol. Methods, 1994, 171 (1), 131-137.
43. Pham, W.; Lai, W. F.; Weissleder, R.; Tung, C. H. High efficiency synthesis of a bioconjugatable near-infrared fluorochrome. Bioconjugate Chemistry, 2003, 14 (5), 1048-1051.
44. Licha, K.; Debus, N.; Emig-Vollmer, S.; Hofmann, B.; Hasbach, M.; Stibenz, D.; Sydow, S.; Schirner, M.; Ebert, B.; Petzelt, D.; Buhrer, C.; Semmler, W.; Tauber, R. Optical molecular imaging of lymph nodes using a targeted vascular contrast agent. J. Biomed. Opt., 2005, 10 (4), 6.
45. Ntziachristos, V.; Bremer, C.; Weissleder, R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol., 2003, 13 (1), 195-208.
46. Licha, K.; Olbrich, C. Optical imaging in drug discovery and diagnostic applications. Advanced Drug Delivery Reviews, 2005, 57 (8), 1087-1108.
47. Kim, S.; Lim, Y. T.; Soltesz, E. G.; De Grand, A. M.; Lee, J.; Nakayama, A.; Parker, J. A.; Mihaljevic, T.; Laurence, R. G.; Dor, D. M.; Cohn, L. H.; Bawendi, M. G.; Frangioni, J. V. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nature Biotechnology, 2004, 22 (1), 93-97.
48. Achilefu, S.; Jimenez, H. N.; Dorshow, R. B.; Bugaj, J. E.; Webb, E. G.; Wilhelm, R. R.; Rajagopalan, R.; Johler, J.; Erion, J. L. Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J. Med. Chem., 2002, 45 (10), 2003-2015.
49. Cheng, Z.; Wu, Y.; Xiong, Z. M.; Gambhir, S. S.; Chen, X. Y. Near-infrared fluorescent RGD peptides for optical imaging of integrin alpha(v)beta 3 expression in living mice. Bioconjugate Chemistry, 2005, 16 (6), 1433-1441.
50. Edwards, W. B.; Xu, B.; Akers, W.; Cheney, P. P.; Liang, K.; Rogers, B. E.; Anderson, C. J.; Achilefu, S. Agonist-antagonist dilemma in molecular imaging: Evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjugate Chemistry, 2008, 19 (1), 192-200.
51. Pysz, M. A.; Gambhir, S. S.; Willmann, J. K. Molecular imaging: current status and emerging strategies. Clin. Radiol., 2010, 65 (7), 500-516.
52. Mallidi, S.; Luke, G. P.; Emelianov, S. Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance. Trends Biotechnol., 2011, 29 (5), 213-221.
53. Li, M. L.; Oh, J. T.; Xie, X. Y.; Ku, G.; Wang, W.; Li, C.; Lungu, G.; Stoica, G.; Wang, L. V. Simultaneous molecular and hypoxia imaging of brain tumors in vivo using spectroscopic photoacoustic tomography. Proc. IEEE, 2008, 96 (3), 481-489.
54. Cui, H. Z.; Yang, X. M. In vivo imaging and treatment of solid tumor using integrated photoacoustic imaging and high intensity focused ultrasound system. Medical Physics, 2010, 37 (9), 4777-4781.
55. Solomon, M.; Liu, Y.; Berezin, M. Y.; Achilefu, S. Optical imaging in cancer research: Basic principles, tumor detection, and therapeutic monitoring. Med. Princ. Pract., 2011, 20 (5), 397-415.
56. Cai, W.; Chen, X. Nanoplatforms for targeted molecular imaging in living subjects. Small, 2007, 3 (11), 1840-54.
57. Strijkers, G. J.; Kluza, E.; Van Tilborg, G. A. F.; van der Schaft, D. W. J.; Griffioen, A. W.; Mulder, W. J. M.; Nicolay, K. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis, 2010, 13 (2), 161-173.
58. Kabalka, G. W.; Davis, M. A.; Holmberg, E.; Maruyama, K.; Huang, L. Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain-length-Targeted MRI contrast enhancement agents for the liver. Magnetic Resonance Imaging, 1991, 9 (3), 373-377.
59. Kabalka, G. W.; Davis, M. A.; Moss, T. H.; Buonocore, E.; Hubner, K.; Holmberg, E.; Maruyama, K.; Huang, L. Gadoliniumlabeled liposomes containing various amphiphilic Gd-DTPA derivatives-Targeted MRI contrast enhancement agents for the liver Magnetic Resonance in Medicine, 1991, 19 (2), 406-415.
60. Hak, S.; Sanders, H.; Agrawal, P.; Langereis, S.; Grull, H.; Keizer, H. M.; Arena, F.; Terreno, E.; Strijkers, G. J.; Nicolay, K. A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur. J. Pharm. Biopharm., 2009, 72 (2), 397-404.
61. Montet, X.; Funovics, M.; Montet-Abou, K.; Weissleder, R.; Josephson, L. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem., 2006, 49 (20), 6087-6093.
62. Montet, X.; Montet-Abou, K.; Reynolds, F.; Weissleder, R.; Josephson, L. Nanoparticle imaging of integrins on tumor cells. Neoplasia, 2006, 8 (3), 214-222.
63. Emerich, D. F.; Thanos, C. G. Multifunctional peptide-based nanosystems for improving delivery and molecular imaging. Curr. Opin. Mol. Ther., 2008, 10 (2), 132-139.
64. Bhattacharya, R.; Mukherjee, P. Biological properties of "naked" metal nanoparticles. Advanced Drug Delivery Reviews, 2008, 60 (11), 1289-1306.
65. Lacroix, L. M.; Ho, D.; Sun, S. H. Magnetic nanoparticles as both imaging probes and therapeutic agents. Curr. Top. Med. Chem., 2010, 10 (12), 1184-1197.
66. Xie, J.; Huang, J.; Li, X.; Sun, S.; Chen, X. Iron oxide nanoparticle platform for biomedical applications. Curr. Med. Chem., 2009, 16 (10), 1278-1294.
67. Xu, C. J.; Sun, S. H. Monodisperse magnetic nanoparticles for biomedical applications. Polym. Int., 2007, 56 (7), 821-826.
68. Sun, S. H. Recent advances in chemical synthesis, self-assembly, and applications of FePt nanoparticles. Adv. Mater., 2006, 18 (4), 393-403.
69. Chen, W.; Kim, J. M.; Sun, S. H.; Chen, S. W. Electrocatalytic reduction of oxygen by FePt alloy nanoparticles. J. Phys. Chem. C, 2008, 112 (10), 3891-3898.
70. Connor, E. E.; Mwamuka, J.; Gole, A.; Murphy, C. J.; Wyatt, M. D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 2005, 1 (3), 325-327.
71. Brust, M.; Fink, J.; Bethell, D.; Schiffrin, D. J.; Kiely, C. Synthesis and reactions of functionalized gold nanoparticles J. Chem. Soc.-Chem. Commun., 1995, (16), 1655-1656.
72. Pissuwan, D.; Valenzuela, S. M.; Cortie, M. B. Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol., 2006, 24 (2), 62-67.
73. Ocampo-Garcia, B. E.; Ramirez, F. D.; Ferro-Flores, G.; De Leon-Rodriguez, L. M.; Santos-Cuevas, C. L.; Morales-Avila, E.; de Murphy, C. A.; Pedraza-Lopez, M.; Medina, L. A.; Camacho-Lopez, M. A. Tc-99m-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. Nucl. Med. Biol., 2011, 38 (1), 1-11.
74. Patra, C. R.; Bhattacharya, R.; Mukhopadhyay, D.; Mukherjee, P. Application of gold nanoparticles for targeted therapy in cancer. J. Biomed. Nanotechnol., 2008, 4 (2), 99-132.
75. Mendoza-Sanchez, A. N.; Ferro-Flores, G.; Ocampo-Garcia, B. E.; Morales-Avila, E.; Ramirez, F. D.; De Leon-Rodriguez, L. M.; Santos-Cuevas, C. L.; Medina, L. A.; Rojas-Calderon, E. L.; Camacho-Lopez, M. A. Lys(3)-Bombesin conjugated to Tc-99mlabelled gold nanoparticles for in vivo gastrin releasing peptidereceptor imaging. J. Biomed. Nanotechnol., 2010, 6 (4), 375-384.
76. Chompoosor, A.; Han, G.; Rotello, V. M. Charge dependence of ligand release and monolayer stability of gold nanoparticles by biogenic thiols. Bioconjugate Chemistry, 2008, 19 (7), 1342-1345.
77. Surujpaul, P. P.; Gutierrez-Wing, C.; Ocampo-Garcia, B.; Ramirez, F. D.; de Murphy, C. A.; Pedraza-Lopez, M.; Camacho-Lopez, M. A.; Ferro-Flores, G. Gold nanoparticles conjugated to Tyr(3) Octreotide peptide. Biophys. Chem., 2008, 138 (3), 83-90.
78. Han, M. Y.; Gao, X. H.; Su, J. Z.; Nie, S. Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nature Biotechnology, 2001, 19 (7), 631-635.
79. Chan, W. C. W.; Maxwell, D. J.; Gao, X. H.; Bailey, R. E.; Han, M. Y.; Nie, S. M. Luminescent quantum dots for multiplexed biological detection and imaging. Curr. Opin. Biotechnol., 2002, 13 (1), 40-46.
80. Rhyner, M. N.; Smith, A. M.; Gao, X. H.; Mao, H.; Yang, L. L.; Nie, S. M. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine, 2006, 1 (2), 209-217.
81. Gao, X. H.; Nie, S. M. Quantum dot-encoded mesoporous beads with high brightness and uniformity: Rapid readout using flow cytometry. Anal. Chem., 2004, 76 (8), 2406-2410.
82. Eggenberger, K.; Frey, N.; Zienicke, B.; Siebenbrock, J.; Schunck, T.; Fischer, R.; Brase, S.; Birtalan, E.; Nann, T.; Nick, P. Use of nanoparticles to study and manipulate plant cells. Advanced Engineering Materials, 2010, 12 (9), B406-B412.
83. Gao, X. H.; Yang, L. L.; Petros, J. A.; Marshal, F. F.; Simons, J. W.; Nie, S. M. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol., 2005, 16 (1), 63-72.
84. Bailey, R. E.; Nie, S. M. Alloyed semiconductor quantum dots: Tuning the optical properties without changing the particle size. J. Am. Chem. Soc., 2003, 125 (23), 7100-7106.
85. Yu, W. W.; Wang, Y. A.; Peng, X. G. Formation and stability of size-, shape-, and structure-controlled CdTe nanocrystals: Ligand effects on monomers and nanocrystals. Chem. Mat., 2003, 15 (22), 4300-4308.
86. Manna, L.; Milliron, D. J.; Meisel, A.; Scher, E. C.; Alivisatos, A. P. Controlled growth of tetrapod-branched inorganic nanocrystals. Nat. Mater., 2003, 2 (6), 382-385.
87. Milliron, D. J.; Hughes, S. M.; Cui, Y.; Manna, L.; Li, J. B.; Wang, L. W.; Alivisatos, A. P. Colloidal nanocrystal heterostructures with linear and branched topology. Nature, 2004, 430 (6996), 190-195.
88. Dick, K. A.; Deppert, K.; Larsson, M. W.; Martensson, T.; Seifert, W.; Wallenberg, L. R.; Samuelson, L. Synthesis of branched 'nanotrees' by controlled seeding of multiple branching events. Nat. Mater., 2004, 3 (6), 380-384.
89. Obonyo, O.; Fisher, E.; Edwards, M.; Douroumis, D. Quantum dots synthesis and biological applications as imaging and drug delivery systems. Critical Reviews in Biotechnology, 2010, 30 (4), 283-301.
90. Gao, X. H.; Cui, Y. Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S. M. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnology, 2004, 22 (8), 969-976.
91. Cai, W.; Chen, X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc, 2008, 3 (1), 89-96.
92. Li, J. B.; Wu, D. D.; Miao, Z. R.; Zhang, Y. Preparation of Quantum Dot bioconjugates and their applications in bio-Imaging. Current Pharmaceutical Biotechnology, 2010, 11 (6), 662-671.
93. Smith, A. M.; Duan, H.; Mohs, A. M.; Nie, S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev, 2008, 60 (11), 1226-40.
94. Young, S. H.; Rozengurt, E. Qdot nanocrystal conjugates conjugated to bombesin or ANG II label the cognate G proteincoupled receptor in living cells. Am. J. Physiol.-Cell Physiol., 2006, 290 (3), C728-C732.
95. Shah, B. S.; Clark, P. A.; Moioli, E. K.; Stroscio, M. A.; Mao, J. J. Labeling of mesenchymal stem cells by bioconjugated quantum dots. Nano Lett, 2007, 7 (10), 3071-9.
96. Zrazhevskiy, P.; Sena, M.; Gao, X. H. Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem. Soc. Rev., 2010, 39 (11), 4326-4354.
97. Kim, J. W.; Galanzha, E. I.; Shashkov, E. V.; Moon, H. M.; Zharov, V. P. Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nature Nanotechnology, 2009, 4 (10), 688-694.
98. Liu, Z.; Tabakman, S.; Welsher, K.; Dai, H. J. Carbon nanotubes in biology and medicine: In vitro and in vivo detection, imaging and drug delivery. Nano Research, 2009, 2 (2), 85-120.
99. Keren, S.; Zavaleta, C.; Cheng, Z.; de la Zerda, A.; Gheysens, O.; Gambhir, S. S. Noninvasive molecular imaging of small living subjects using Raman spectroscopy. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105 (15), 5844-5849.
100. Weckbecker, G.; Lewis, I.; Albert, R.; Schmid, H. A.; Hoyer, D.; Bruns, C. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects (vol 2, pg 999, 2003). Nature Reviews Drug Discovery, 2005, 4 (12), 975-975.
101. Susini, C.; Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol., 2006, 17 (12), 1733-1742.
102. Kwekkeboom, D. J.; Krenning, E. P. Somatostatin receptor imaging. Seminars in Nuclear Medicine, 2002, 32 (2), 84-91.
103. De Jong, M.; Bakker, W. H.; Breeman, W. A. P.; Bernard, B. F.; Hofland, L. J.; Visser, T. J.; Srinivasan, A.; Schmidt, M.; Behe, M.; Macke, H. R.; Krenning, E. P. Pre-clinical comparison of DTPA(0) octreotide, DTPA(0), Tyr(3) octreotide and DOTA(0), Tyr(3) octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int. J. Cancer, 1998, 75 (3), 406-411.
104. Kwekkeboom, D. J.; Kam, B. L.; Bakker, W. H.; Kooij, P. P.; de Herder, W. W.; Srinivasan, A.; Erion, J. L.; Bugaj, J. L.; Schmidt, M. A.; de Jong, M.; Krenning, E. P. Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors. J. Nucl. Med., 2002, 43 (5), 123.
105. Jamar, F.; Barone, R.; Mathieu, I.; Walrand, S.; Labar, D.; Carlier, P.; de Camps, J.; Schran, H.; Chen, T.; Smith, M. C.; Bouterfa, H.; Valkema, R.; Krenning, E. P.; Kvols, L. K.; Pauwels, S. Y-86-DOTA(0)-D-Phe(1)-Tyr(3)-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30 (4), 510-518.
106. Rodriguez-Cortes, J.; De Murphy, C. A.; Ferro-Flores, G.; Pedraza-Lopez, M.; Murphy-Stack, E. Biokinetics and dosimetry with Lu-177-DOTA-TATE in athymic mice with induced pancreatic malignant tumours: preclinical studies. Radiat. Eff. Defects Solids, 2007, 162 (10-12), 791-796.
107. Laznicek, M.; Laznickova, A.; Melicharova, L.; Cihlo, J. Preclinical comparison of DOTA-TATE and DOTA-NOC labelled with in-111. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, S335-S335.
108. Virgolini, I.; Kurtaran, A.; Smith-Jones, P.; Havlik, E.; Traub, T.; Leimer, M.; Ofluoglu, S.; Andreae, F.; Raderer, M.; Angelberger, P.; Becherer, A.; Niederle, B.; Kletter, K.; Schima, W.; Dudczak, R. Comparative study of In-111-DOTA-Lanreotide (LAN), In-111-DTPA-D-Phe-1-Octreotide (OCT), In-111-DOTA-Tyr-3-Octreotide (TOCT) and F-18-FDG-PET in neuroendocrine tumor patients. Eur. J. Nucl. Med., 1999, 26 (9), PS413.
109. Rodrigues, M.; Ibi, B.; Traub-Weidinger, T.; Li, S.; Virgolini, I. Comparison of In-111-DOTA-DPhe(1)-Tyr(3)-octreotide and (111)InDOTA-lanreotide dosimetry for therapy planning of patients with somatostatin receptor positive tumours. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, S102-S102.
110. Kabasakal, L.; Sager, S.; Nisli, C.; Maecke, H.; Onsel, C.; Uslu, I. Clinical experience with Tc-99m Hynic/TOC and Tc-99m Hynic/TATE in somatostatin receptor positive lesions: Preliminary report. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, S358-S358.
111. Hubalewska, A.; Fross, K.; Staszczak, A.; Huszno, B.; Szybinski, P.; Kulig, J.; Mikolajczak, R.; Gorska, B. Detection of somatostatin receptor-positive neuroendocrine tumours using Tc-99m-EDDA/HYNIC-TATE-Two-year experience. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, S214-S214.
112. Czepczynski, R.; Kosowicz, J.; Mikolajczak, R.; Gryczynska, M.; Ziemnicka, K.; Sowinski, J. Scintigraphy using 99mTc-EDDA/HYNIC-TOC in diagnosis of post-surgical hypercalcitoninemia in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, S245-S245.
113. Decristoforo, C.; Melendez-Alafort, L.; Sosabowski, J. K.; Mather, S. J. Tc-99m-HYNIC-Tyr(3)-octreotide for imaging somatostatinreceptor-positive tumors: Preclinical evaluation and comparison with In-111-octreotide. J. Nucl. Med., 2000, 41 (6), 1114-1119.
114. Gonzalez-Vazquez, A.; Ferro-Flores, G.; De Murphy, C. A.; Gutierrez-Garcia, Z. Biokinetics and dosimetry in patients of Tc-99m-EDDA/HYNIC-Tyr(3)-octreotide prepared from lyophilized kits. Appl. Radiat. Isot., 2006, 64 (7), 792-797.
115. Plachcinska, A.; Mikolajczak, R.; Maecke, H. R.; Michalski, A.; Rzeszutek, K.; Kozak, J.; Kusmierek, J. Tc-99m-EDDA/HYNICTOC scintigraphy in the differential diagnosis of solitary pulmonary nodules. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31 (7), 1005-1010.
116. Plachcinska, A.; Mikolajczak, R.; Maecke, H. R.; Mlodkowska, E.; Kunert-Radek, J.; Michalski, A.; Rzeszutek, K.; Kozak, J.; Kusmierek, J. Clinical usefulness of Tc-99m-EDDA/HYNICTOC scintigraphy in oncological diagnostics: a preliminary communication. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30 (10), 1402-1406.
117. Karathanos, E.; Datseris, I.; Vlontzou, E.; Zisimopoulos, A.; Georgiou, E. Contribution of Tc-99m-depreotide (Neospect) scintigraphy in lung cancer staging. J. Buon, 2010, 15 (1), 147-152.
118. Apostolopoulos, D. J.; Papandrianos, N. I.; Symeonidis, A.; Spyridonidis, T.; Alexiou, S.; Zampakis, P.; Savvopoulos, C.; Vassilakos, P. J.; Matsouka, P. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. Ann. Nucl. Med., 2010, 24 (9), 639-647.
119. Gabriel, M.; Maina, T.; Nock, B.; Cordopatis, P.; Moncayo, R.; Decristoforo, C. First experience with Tc-99m-Demotate 1 in patients in comparison with Tc-99m-EDDA/HYNIC-TOC. Cancer Biother. Radiopharm., 2003, 18 (2), 285-286.
120. Decristoforo, C.; Maina, T.; Nock, B.; Gabriel, M.; Cordopatis, P.; Moncayo, R. 99(m)Tc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30 (9), 1211-1219.
121. Maecke, H. R.; Reubi, J. C. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J. Nucl. Med., 2011, 52 (6), 841-844.
122. Shokeen, M.; Anderson, C. J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and Positron Emission Tomography (PET). Accounts of Chemical Research, 2009, 42 (7), 832-841.
123. Madleitner, R.; Kendler, D.; Putzer, D.; Gabriel, M.; Uprimny, C.; Bale, R. J.; Donnemiller, E.; Virgolini, I. J. Clinical value of 68Ga-DOTA-Tyr3-Octreotide PET imaging in patients with Paragangliomas-a pilot study. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, S297-S297.
124. Kwekkeboom, D. J.; Kam, B. L.; van Essen, M.; Teunissen, J. J. M.; van Eijck, C. H. J.; Valkema, R.; de Jong, M.; de Herder, W. W.; Krenning, E. P. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2010, 17 (1), R53-R73.
125. Dimitrakopoulou-Strauss, A.; Georgoulias, V.; Eisenhut, M.; Herth, F.; Koukouraki, S.; Macke, H. R.; Haberkorn, U.; Strauss, L. G. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using Ga-68-DOTATOC PET and comparison with F-18-FDG PET. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33 (7), 823-830.
126. Virgolini, I.; Ambrosini, V.; Bomanji, J. B.; Baum, R. P.; Fanti, S.; Gabriel, M.; Papathanasiou, N. D.; Pepe, G.; Oyen, W.; De Cristoforo, C.; Chiti, A. Procedure guidelines for PET/CT tumour imaging with Ga-68-DOTA-conjugated peptides: Ga-68-DOTATOC, Ga-68-DOTA-NOC, Ga-68-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37 (10), 2004-2010.
127. Szalus, N.; Pawlak, D.; Dziuk, M.; Koza, M.; Kaminski, G.; Podgajny, Z.; Dziuk, E. 68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of the extent of the disease in patients with malignant endocrine tumors: Our experience (preliminary results). Neuroendocrinology, 2010, 92 (1), 60-61.
128. Traub-Weidinger, T.; von Guggenberg, E.; Dobrozemsky, G.; Kendler, D.; Eisterer, W.; Bale, R.; Heute, D.; Gabriel, M.; Decristoforo, C.; Virgolini, I. First experiences with ga-68-DOTAlanreotide PET in tumor patients. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, S123-S123.
129. Traub-Weidinger, T.; Von Guggenberg, E.; Dobrozemsky, G.; Kendler, D.; Eisterer, W.; Bale, R.; Putzer, D.; Gabriel, M.; Virgolini, I. Preliminary experience with Ga-68-DOTA-lanreotide positron emission tomography. Q. J. Nucl. Med. Mol. Imag., 2010, 54 (1), 52-60.
130. Fanti, S.; Ambrosini, V.; Tomassetti, P.; Castellucci, P.; Montini, G.; Allegri, V.; Grassetto, G.; Rubello, D.; Nanni, C.; Franchi, R. Evaluation of unusual neuroendocrine tumours by means of Ga-68-DOTA-NOC PET. Biomed. Pharmacother., 2008, 62 (10), 667-671.
131. Ambrosini, V.; Campana, D.; Allegri, V.; Opocher, G.; Fanti, S. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von Hippel-Lindau cerebellar disease. Clin. Nucl. Med., 2011, 36 (1), 64-65.
132. Anderson, C. J.; Dehdashti, F.; Cutler, P. D.; Schwarz, S. W.; Laforest, R.; Bass, L. A.; Lewis, J. S.; McCarthy, D. W. Cu-64-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med., 2001, 42 (2), 213-221.
133. Meisetschlager, G.; Poethko, T.; Stahl, A.; Wolf, I.; Scheidhauer, K.; Schottelius, M.; Herz, M.; Wester, H. J.; Schwaiger, M. Gluc-Lys(F-18 FP)-TOCA PET in patients with SSTR-positive tumors: Biodistribution and diagnostic evaluation compared with In-111 DTPA-octreotide. J. Nucl. Med., 2006, 47 (4), 566-573.
134. Schottelius, M.; Poethko, T.; Herz, M.; Reubi, J. C.; Kessler, H.; Schwaiger, M.; Wester, H. J. First F-18-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clinical Cancer Research, 2004, 10 (11), 3593-3606.
135. Fani, M.; Del Pozzo, L.; Abiraj, K.; Mansi, R.; Tamma, M. L.; Cescato, R.; Waser, B.; Weber, W. A.; Reubi, J. C.; Maecke, H. R. PET of somatostatin receptor-positive tumors using (64)Cu-and (68)Ga-somatostatin antagonists: the chelate makes the difference. J. Nucl. Med., 2011, 52 (7), 1110-1118.
136. Kostenich, G.; Livnah, N.; Bonasera, T. A.; Yechezkel, T.; Salitra, Y.; Litman, P.; Kimel, S.; Orenstein, A. Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin. Lung Cancer, 2005, 50 (3), 319-328.
137. Kostenich, G.; Oron-Herman, M.; Kimel, S.; Livnah, N.; Tsarfaty, I.; Orenstein, A. Diagnostic targeting of colon cancer using a novel fluorescent somatostatin conjugate in a mouse xenograft model. Int. J. Cancer, 2008, 122 (9), 2044-2049.
138. Li, X. B.; Du, X. K.; Huo, T. L.; Liu, X.; Zhang, S.; Yuan, F. Specific targeting of breast tumor by Octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner. Acta Radiol., 2009, 50 (6), 583-594.
139. Helbok A; Rangger C; von Guggenberg E; Saba-Lepek M; Radolf T; Thurner G; Andreae F; Prassl R; C., D. Targeting properties of peptide-modified radiolabeled liposomal nanoparticles. Nanomedicine., 2012, 8 (1), 112-118.
140. Schottelius, M.; Laufer, B.; Kessler, H.; Wester, H. J. Ligands for mapping alpha(v)beta(3)-integrin expression in vivo. Accounts of Chemical Research, 2009, 42 (7), 969-980.
141. Beer, A. J.; Schwaiger, M. Imaging of integrin alpha v beta 3 expression. Cancer and Metastasis Reviews, 2008, 27 (4), 631-644.
142. Brooks, P. C.; Clark, R. A. F.; Cheresh, D. A. Requirement of vascular integrin alpha(V)beta(3) for angiogenesis. Science, 1994, 264 (5158), 569-571.
143. Dijkgraaf, I.; Beer, A. J.; Wester, H. J. Application of RGDcontaining peptides as imaging probes for alphavbeta3 expression. Front. Biosci., 2009, 14, 887-899.
144. Beer, A. J.; Haubner, R.; Wolf, I.; Goebel, M.; Luderschmidt, S.; Niemeyer, M.; Grosu, A. L.; Martinez, M. J.; Wester, H. J.; Weber, W. A.; Schwaiger, M. PET-based human dosimetry of F-18-Galacto-RGD, a new radiotracer for imaging alpha v beta 3 expression. J. Nucl. Med., 2006, 47 (5), 763-769.
145. Van de Wiele, C.; Dhaene, K.; Vandenbroeke, R.; Cocquyt, V.; Dumont, F.; De Winter, F.; Slegers, G.; Dierckx, R. A. Gastrin releasing peptide receptor imaging in human breast carcinoma using Tc-99m RP527 versus immunohistochemistry. Eur. J. Nucl. Med., 2001, 28 (8), PS181.
146. Chen, X. Y.; Park, R.; Hou, Y. P.; Khankaldyyan, V.; Gonzales-Gomez, I.; Tohme, M.; Bading, J. R.; Laug, W. E.; Conti, P. S. MicroPET imaging of brain tumor angiogenesis with F-18-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31 (8), 1081-1089.
147. Zhang, X. Z.; Xiong, Z. M.; Wu, Y.; Cai, W. B.; Tseng, J. R.; Gambhir, S. S.; Chen, X. Y. Quantitative PET imaging of tumor integrin alpha(v)beta(3) expression with F-18-FRGD2. J. Nucl. Med., 2006, 47 (1), 113-121.
148. Chen, X. Y.; Park, R.; Shahinian, A. H.; Tohme, M.; Khankaldyyan, V.; Bozorgzadeh, M. H.; Bading, J. R.; Moats, R.; Laug, W. E.; Conti, P. S. F-18-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol., 2004, 31 (2), 179-189.
149. Li, Z. B.; Wu, Z.; Chen, K.; Chin, F. T.; Chen, X. Click chemistry for F-18-labeling of RGD peptides and microPET Imaging of tumor integrin alpha(v)beta(3) expression. Bioconjugate Chemistry, 2007, 18 (6), 1987-1994.
150. Chen, X. Y.; Liu, S.; Hou, Y. P.; Tohme, M.; Park, R.; Bading, J. R.; Conti, P. S. MicroPET imaging of breast cancer alpha(v)-integrin expression with Cu-64-labeled dimeric RGD peptides. Molecular Imaging and Biology, 2004, 6 (5), 350-359.
151. Li, Z. B.; Chen, K.; Chen, X. Ga-68-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta(3) expression. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35 (6), 1100-1108.
152. Shi, J. Y.; Wang, L. J.; Kim, Y. S.; Zhai, S. Z.; Liu, Z. F.; Chen, X. Y.; Liu, S. Improving tumor uptake and excretion kinetics of (99m)Tc-labeled cyclic Arginine-Glycine-Aspartic (RGD) dimers with Triglycine linkers. J. Med. Chem., 2008, 51 (24), 7980-7990.
153. Wang, L. J.; Shi, J. Y.; Kim, Y. S.; Zhai, S. Z.; Jia, B.; Zhao, H. Y.; Liu, Z. F.; Wang, F.; Chen, X. Y.; Liu, S. Improving tumortargeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Molecular Pharmaceutics, 2009, 6 (1), 231-245.
154. Sivolapenko, G. B.; Skarlos, D.; Pectasides, D.; Stathopoulou, E.; Milonakis, A.; Sirmalis, G.; Stuttle, A.; Courtenay-Luck, N. S.; Konstantinides, K.; Epenetos, A. A. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur. J. Nucl. Med., 1998, 25 (10), 1383-1389.
155. Bach-Gansmo, T.; Danielsson, R.; Saracco, A.; Wilczek, B.; Bogsrud, T. V.; Fangberget, A.; Tangerud, A.; Tobin, D. Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate Tc-99m-NC100692. J. Nucl. Med., 2006, 47 (9), 1434-1439.
156. Beer, A. J.; Grosu, A. L.; Carlsen, J.; Kolk, A.; Sarbia, M.; Stangier, I.; Watzlowik, P.; Wester, H. J.; Haubner, R.; Schwaiger, M. F-18 Galacto-RGD positron emission tomography for imaging of alpha v beta 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research, 2007, 13 (22), 6610-6616.
157. Schnell, O.; Krebs, B.; Carlsen, J.; Miederer, I.; Goetz, C.; Goldbrunner, R. H.; Wester, H. J.; Haubner, R.; Popperl, G.; Holtmannspotter, M.; Kretzschmar, H. A.; Kessler, H.; Tonn, J. C.; Schwaiger, M.; Beer, A. J. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by F-18 Galacto-RGD positron emission tomography. Neuro-Oncology, 2009, 11 (6), 861-870.
158. Kenny, L. M.; Coombes, R. C.; Oulie, I.; Contractor, K. B.; Miller, M.; Spinks, T. J.; McParland, B.; Cohen, P. S.; Hui, A. M.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; At-Nahhas, A.; Aboagye, E. O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand F-18-AH111585 in breast cancer patients. J. Nucl. Med., 2008, 49 (6), 879-886.
159. Kolb, H. C.; Chen, K.; Walsh, J. C.; Chen, G.; Gangadharmath, U.; Kasi, D.; Scott, R.; Haka, M.; Collier, T. L.; Padgett, H. C.; Zhu, Z.; Liang, Q.; Zhao, T.; Secrest, J.; Gomez, L. F. Synthesis and imaging of an 18F-labeled RGD peptide for detecting alpha v beta 3 integrin expression in vivo J. Label. Compd. Radiopharm., 2009, 52, S67-S67.
160. Sun, X. L.; Yan, Y. J.; Liu, S. L.; Cao, Q. Z.; Yang, M.; Neamati, N.; Shen, B. Z.; Niu, G.; Chen, X. Y. F-18-FPPRGD2 and F-18-FDG PET of response to abraxane therapy. J. Nucl. Med., 2011, 52 (1), 140-146.
161. Hsu, A. R.; Hou, L. C.; Veeravagu, A.; Greve, J. M.; Vogel, H.; Tse, V.; Chen, X. Y. In vivo near-infrared fluorescence imaging of integrin alpha(v)beta(3) in an orthotopic glioblastoma model. Molecular Imaging and Biology, 2006, 8 (6), 315-323.
162. Chen, X. Y.; Conti, P. S.; Moats, R. A. In vivo near-infrared fluorescence imaging of integrin a, alpha(v)beta(3) in brain tumor xenografts. Cancer Res., 2004, 64 (21), 8009-8014.
163. Achilefu, S.; Bloch, S.; Markiewicz, M. A.; Zhong, T. X.; Ye, Y. P.; Dorshow, R. B.; Chance, B.; Liang, K. X. Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102 (22), 7976-7981.
164. Bloch, S.; Lesage, F.; McIntosh, L.; Gandjbakhche, A.; Liang, K. X.; Achilefu, S. Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice. J. Biomed. Opt., 2005, 10 (5), 8.
165. Wang, W.; Ke, S.; Wu, Q.; Charnsangavej, C.; Gurfinkel, M.; Gelovani, J. G.; Abbruzzese, J. L.; Sevick-Muraca, E. M.; Li, C. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging, 2004, 3 (4), 343-51.
166. Gurfinkel, M.; Ke, S.; Wang, W.; Li, C.; Sevick-Muraca, E. M. Quantifying molecular specificity of alpha(v)beta(3) integrintargeted optical contrast agents with dynamic optical imaging. J. Biomed. Opt., 2005, 10 (3), 9.
167. Jin, Z. H.; Josserand, V.; Foillard, S.; Boturyn, D.; Dumy, P.; Favrot, M. C.; Coll, J. L. In vivo optical imaging of integrin alpha(v)-beta(3) in mice using multivalent or monovalent cRGD targeting vectors. Molecular Cancer, 2007, 6, 9.
168. Jin, Z. H.; Josserand, V.; Razkin, J.; Garanger, E.; Boturyn, D.; Favrot, M. C.; Dumy, P.; Coll, J. L. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)(4). Molecular Imaging, 2006, 5 (3), 188-197.
169. Jin, Z. H.; Furukawa, T.; Waki, A.; Akaji, K.; Coll, J. L.; Saga, T.; Fujibayashi, Y. Effect of multimerization of a linear Arg-Gly-Asp peptide on integrin binding affinity and specificity. Biological & Pharmaceutical Bulletin, 2010, 33 (3), 370-378.
170. Jin, Z. H.; Razkin, J.; Josserand, V.; Boturyn, D.; Grichine, A.; Texier, I.; Favrot, M. C.; Dumy, P.; Coll, J. L. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4). Molecular Imaging, 2007, 6 (1), 43-55.
171. Ye, Y. P.; Bloch, S.; Xu, B. G.; Achilefu, S. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J. Med. Chem., 2006, 49 (7), 2268-2275.
172. Kimura, R. H.; Cheng, Z.; Gambhir, S. S.; Cochran, J. R. Engineered Knottin peptides: A new class of agents for imaging integrin expression in living subjects. Cancer Res., 2009, 69 (6), 2435-2442.
173. Liu, Z. F.; Liu, S. L.; Niu, G.; Wang, F.; Liu, S.; Chen, X. Y. Optical imaging of integrin alpha(v)beta(3) expression with nearinfrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Molecular Imaging, 2010, 9 (1), 21-29.
174. Ye, Y. P.; Zhu, L.; Ma, Y.; Niu, G.; Chen, X. Y. Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorganic & Medicinal Chemistry Letters, 2011, 21 (4), 1146-1150.
175. von Wallbrunn, A.; Holtke, C.; Zuhlsdorf, M.; Heindel, W.; Schafers, M.; Bremer, C. In vivo imaging of integrin alpha nu beta(3) expression using fluorescence-mediated tomography. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34 (5), 745-754.
176. Kossodo, S.; Pickarski, M.; Lin, S. A.; Gleason, A.; Gaspar, R.; Buono, C.; Ho, G. J.; Blusztajn, A.; Cuneo, G.; Zhang, J.; Jensen, J.; Hargreaves, R.; Coleman, P.; Hartman, G.; Rajopadhye, M.; Duong, L. T.; Sur, C.; Yared, W.; Peterson, J.; Bednar, B. Dual in vivo quantification of Integrin-targeted and protease-activated agents in cancer using Fluorescence Molecular Tomography (FMT). Molecular Imaging and Biology, 2010, 12 (5), 488-499.
177. Wu, P.; He, X. X.; Wang, K. M.; Tan, W. H.; Ma, D.; Yang, W. H.; He, C. M. Imaging breast cancer cells and tissues using peptidelabeled fluorescent silica nanoparticles. Journal of Nanoscience and Nanotechnology, 2008, 8 (5), 2483-2487.
178. Xie, J.; Chen, K.; Lee, H. Y.; Xu, C. J.; Hsu, A. R.; Peng, S.; Chen, X. Y.; Sun, S. H. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta(3)-rich tumor cells. J. Am. Chem. Soc., 2008, 130 (24), 7542-+.
179. Chen, K.; Xie, J.; Xu, H. Y.; Behera, D.; Michalski, M. H.; Biswal, S.; Wang, A.; Chen, X. Y. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials, 2009, 30 (36), 6912-6919.
180. Yu, M. K.; Park, J.; Jeong, Y. Y.; Moon, W. K.; Jon, S. Integrintargeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery. Nanotechnology, 2010, 21 (41), 9.
181. Li, Z. M.; Huang, P.; Zhang, X. J.; Lin, J.; Yang, S.; Liu, B.; Gao, F.; Xi, P.; Ren, Q. S.; Cui, D. X. RGD-conjugated dendrimermodified gold nanorods for in vivo tumor targeting and photothermal therapy. Molecular Pharmaceutics, 2010, 7 (1), 94-104.
182. Yong, K. T. Biophotonics and biotechnology in pancreatic cancer: cyclic RGD-peptide-conjugated type II Quantum Dots for in vivo imaging. Pancreatology, 2010, 10 (5), 553-564.
183. Yong, K. T.; Hu, R.; Roy, I.; Ding, H.; Vathy, L. A.; Bergey, E. J.; Mizuma, M.; Maitra, A.; Prasad, P. N. Tumor targeting and imaging in live animals with functionalized semiconductor Quantum Rods. Acs Applied Materials & Interfaces, 2009, 1 (3), 710-719.
184. Cai, W. B.; Shin, D. W.; Chen, K.; Gheysens, O.; Cao, Q. Z.; Wang, S. X.; Gambhir, S. S.; Chen, X. Y. Peptide-labeled nearinfrared quantum dots for imaging tumor vasculature in living subjects. Nano Letters, 2006, 6 (4), 669-676.
185. Gao, J. H.; Chen, K.; Xie, R. G.; Xie, J.; Yan, Y. J.; Cheng, Z.; Peng, X. G.; Chen, X. Y. In vivo tumor-targeted fluorescence imaging using near-infrared non-Cadmium Quantum Dots. Bioconjugate Chemistry, 2010, 21 (4), 604-609.
186. He, X. X.; Gao, J. H.; Gambhir, S. S.; Cheng, Z. Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. Trends Mol. Med, 2010, 16 (12), 574-583.
187. Pan, D.; Pramanik, M.; Senpan, A.; Allen, J. S.; Zhang, H. Y.; Wickline, S. A.; Wang, L. V.; Lanza, G. M. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. Faseb J., 2011, 25 (3), 875-882.
188. de Visser, M.; van Weerden, W. M.; de Ridder, C. M. A.; Reneman, S.; Melis, M.; Krenning, E. P.; de Jong, M. Androgendependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J. Nucl. Med., 2007, 48 (1), 88-93.
189. de Wiele, C. V.; Phonteyne, P.; Pauwels, P.; Goethals, I.; Van den Broecke, R.; Cocquyt, V.; Dierckx, R. A. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J. Nucl. Med., 2008, 49 (2), 260-264.
190. Di Santo, G.; Archimandritis, S.; Soluri, A.; Trotta, C.; Massari, R.; Parisella, M. G.; Anastasia, A.; Mattei, M.; Monteleone, F.; Chiacchiararelli, L.; Varvarigou, A.; Scopinaro, F. High-resolution scintigraphy and Tc-99m Bombesin are able to guide Mammotome biopsy and to detect lymph node invasion. Nucl. Instrum. Methods Phys. Res. Sect. A-Accel. Spectrom. Dect. Assoc. Equip., 2006, 569 (2), 171-174.
191. Scopinaro, F.; Di Santo, G. P.; Tofani, A.; Massari, R.; Trotta, C.; Ragone, M.; Archimandritis, S.; Varvarigou, A. D. Fast cancer uptake of Tc-99m-labelled bombesin (Tc-99m BN1). In Vivo, 2005, 19 (6), 1071-1076.
192. Scopinaro, F.; Varvarigou, A. D.; Ussof, W.; De Vincentis, G.; Sourlingas, T. G.; Evangelatos, G. P.; Datsteris, J.; Archimandritis, S. C. Technetium labeled bombesin-like peptide: Preliminary report on breast cancer uptake in patients. Cancer Biother. Radiopharm., 2002, 17 (3), 327-335.
193. Van de Wiele, C.; Dumont, F.; Vanden Broecke, R.; Oosterlinck, W.; Cocquyt, V.; Serreyn, R.; Peers, S.; Thornback, J.; Slegers, G.; Dierckx, R. A. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl. Med., 2000, 27 (11), 1694-1699.
194. Ferro-Flores, G.; de Murphy, C. A.; Rodriguez-Cortes, J.; Pedraza-Lopez, M.; Ramirez-Iglesias, M. Preparation and evaluation of Tc-99m-EDDA/HYNIC-Lys(3)-bombesin for imaging gastrinreleasing peptide receptor-positive tumours. Nucl. Med. Commun., 2006, 27 (4), 371-376.
195. Santos-Cuevas, C. L.; Ferro-Flores, G.; de Murphy, C. A.; Pichardo-Romero, P. A. Targeted imaging of gastrin-releasing peptide receptors with Tc-99m-EDDA/HYNIC-Lys(3)-bombesin: biokinetics and dosimetry in women. Nucl. Med. Commun., 2008, 29 (8), 741-747.
196. Dimitrakopoulou-Strauss, A.; Hohenberger, P.; Haberkorn, U.; Macke, H. R.; Eisenhut, M.; Strauss, L. G. Ga-68-Labeled bombesin studies in patients with gastrointestinal stromal tumors: Comparison with F-18-FDG. J. Nucl. Med., 2007, 48 (8), 1245-1250.
197. Ma, L. X.; Yu, P.; Veerendra, B.; Rold, T. L.; Retzloff, L.; Prasanphanich, A.; Sieckman, G.; Hoffman, T. J.; Volkert, W. A.; Smith, C. J. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin 7-14 NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor. Molecular Imaging, 2007, 6 (3), 171-180.
198. Chanda, N.; Kattumuri, V.; Shukla, R.; Zambre, A.; Katti, K.; Upendran, A.; Kulkarni, R. R.; Kan, P.; Fent, G. M.; Casteel, S. W.; Smith, C. J.; Boote, E.; Robertson, J. D.; Cutler, C.; Lever, J. R.; Katti, K. V.; Kannan, R. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107 (19), 8760-8765.
199. Lee, C. M.; Jeong, H. J.; Cheong, S. J.; Kim, E. M.; Kim, D. W.; Lim, S. T.; Sohn, M. H. Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm. Res., 2010, 27 (4), 712-721.
200. Reubi, J. C.; Schaer, J. C.; Waser, B. Cholecystokinin (CCK)-A and CCK-B gastrin receptors in human tumors. Cancer Res., 1997, 57 (7), 1377-1386.
201. Reubi, J. C. Targeting CCK receptors in human cancers. Curr. Top. Med. Chem., 2007, 7 (12), 1239-1242.
202. Behr, T. M.; Jenner, N.; Radetzky, S.; Behe, M.; Gratz, S.; Yucekent, S.; Raue, F.; Becker, W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur. J. Nucl. Med., 1998, 25 (4), 424-430.
203. de Jong, M.; Bakker, W. H.; Bernard, B. F.; Valkema, R.; Kwekkeboom, D. J.; Reubi, J. C.; Srinivasan, A.; Schmidt, M.; Krenning, E. P. Preclinical and initial clinical evaluation of In-111-labeled nonsulfated CCK8 analog: A peptide for CCK-B receptortargeted scintigraphy and radionuclide therapy. J. Nucl. Med., 1999, 40 (12), 2081-2087.
204. Breeman, W. A. P.; Froberg, A. C.; de Blois, E.; van Gameren, A.; Melis, M.; de Jong, M.; Maina, T.; Nock, B. A.; Erion, J. L.; Macke, H. R.; Krenning, E. P. Optimised labeling, preclinical and initial clinical. aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl. Med. Biol., 2008, 35 (8), 839-849.
205. Behe, M.; Becker, W.; Gotthardt, M.; Angerstein, C.; Behr, T. M. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30 (8), 1140-1146.
206. Gotthardt, M.; Behe, P.; Beuter, D.; Battmann, A.; Bauhofer, A.; Schurrat, T.; Schipper, M.; Pollum, H.; Oyen, W. J. G.; Behr, T. M. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33 (11), 1273-1279.
207. Nock, B. A.; Maina, T.; Behe, M.; Nikolopoulou, A.; Gotthardt, M.; Schmitt, J. S.; Behr, T. M.; Macke, H. R. CCK-2/gastrin receptor-targeted tumor imaging with Tc-99m-labeled minigastrin analogs. J. Nucl. Med., 2005, 46 (10), 1727-1736.
208. Laabs, E.; Behe, M.; Kossatz, S.; Frank, W.; Kaiser, W. A.; Hilger, I. Optical imaging of CCK2/Gastrin receptor-positive tumors with a Minigastrin Near-Infrared probe. Invest. Radiol., 2011, 46 (3), 196-201.
209. Vincent, J. P. Neurotensin receptors: Binding properties, transduction pathways, and structure. Cell. Mol. Neurobiol., 1995, 15 (5), 501-512.
210. Reubi, J. C.; Waser, B.; Friess, H.; Buchler, M.; Laissue, J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut, 1998, 42 (4), 546-550.
211. Buchegger, F.; Bonvin, F.; Kosinski, M.; Schaffland, A. O.; Prior, J.; Reubi, J. C.; Blauenstein, P.; Tourwe, D.; Garayoa, E. G.; Delaloye, A. B. Radiolabeled neurotensin analog, Tc-99m-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J. Nucl. Med., 2003, 44 (10), 1649-1654.
212. Reubi, J. C. In-vitro identification of vasoactive-intestinal-peptide receptors in human tumours-implications for tumor imaging J. Nucl. Med., 1995, 36 (10), 1846-1853.
213. Kurtaran, A.; Leimer, M.; Kaserer, K.; Yang, Q. O.; Angelberger, P.; Niederle, B.; Virgolini, I. Combined use of In-111-DTPA-DPhe-1-octreotide (OCT) and I-123-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl. Med. Biol., 1996, 23 (4), 503-507.
214. Raderer, M.; Kurtaran, A.; Hejna, M.; Vorbeck, F.; Angelberger, P.; Scheithauer, W.; Virgolini, I. I-123-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br. J. Cancer, 1998, 78 (1), 1-5.
215. Raderer, M.; Kurtaran, A.; Leimer, M.; Angelberger, P.; Niederle, B.; Vierhapper, H.; Vorbeck, F.; Hejna, M. H. L.; Scheithauer, W.; Pidlich, J.; Virgolini, I. Value of peptide receptor scintigraphy using I-123-vasoactive intestinal peptide and In-111-DTPA-DPhe(1)-octreotide in 194 carcinoid patients: Vienna university experience, 1993 to 1998. J. Clin. Oncol., 2000, 18 (6), 1331-1336.
216. Raderer, M.; Kurtaran, A.; Yang, Q.; Meghdadi, S.; Vorbeck, F.; Hejna, M.; Angelberger, P.; Kornek, G.; Pidlich, J.; Scheithauer, W.; Virgolini, I. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J. Nucl. Med., 1998, 39 (9), 1570-1575.
217. Virgolini, I.; Raderer, M.; Kurtaran, A.; Angelberger, P.; Yang, Q.; Radosavljevic, M.; Leimer, M.; Kaserer, K.; Li, S. R.; Kornek, G.; Hubsch, P.; Niederle, B.; Pidlich, J.; Scheithauer, W.; Valent, P. I-123-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl. Med. Biol., 1996, 23 (6), 685-692.
218. Rao, P. S.; Thakur, M. L.; Pallela, V.; Patti, R.; Reddy, K.; Li, H.; Sharma, S.; Pham, H. L.; Diggles, L.; Minami, C.; Marcus, C. S. Tc-99m labeled VIP analog: evaluation for imaging colorectal cancer. Nucl. Med. Biol., 2001, 28 (4), 445-450.
219. Thakur, M. L.; Marcus, C. S.; Saeed, S.; Pallela, V.; Minami, C.; Diggles, L.; Le Pham, H.; Ahdoot, R.; Kalinowski, E. A. Tc-99mlabeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J. Nucl. Med., 2000, 41 (1), 107-110.
220. Virgolini, I.; Traub, T.; Ofluoglu, S.; Kurtaran, A.; Raderer, M.; Beck, M.; Leimer, M.; Angelberger, P.; Li, S. R.; Novotny, C.; Havlik, E.; Dudczak, R.; Lister-James, J. Tc-99m P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy: Clinical efficacy, biodistribution and safety. Eur. J. Nucl. Med., 1999, 26 (9), PS408.
221. Mayo, K. E.; Miller, L. J.; Bataille, D.; Dalle, S.; Goke, B.; Thorens, B.; Drucker, D. J. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev., 2003, 55 (1), 167-194.
222. Wild, D.; Behe, M.; Wicki, A.; Storch, D.; Waser, B.; Gotthardt, M.; Keil, B.; Christofori, G.; Reubi, J. C.; Macke, H. R. Lys(40) (Ahx-DTPA-In-111)NH2 exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J. Nucl. Med., 2006, 47 (12), 2025-2033.
223. Korner, M.; Stockli, M.; Waser, B.; Reubi, J. C. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J. Nucl. Med., 2007, 48 (5), 736-743.
224. Christ, E.; Wild, D.; Reubi, J. C. Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: A review. Endocrinol. Metabol. Clin. North Amer., 2010, 39 (4), 791-+.
225. Wild, D.; Wicki, A.; Mansi, R.; Behe, M.; Keil, B.; Bernhardt, P.; Christofori, G.; Ell, P. J.; Macke, H. R. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J. Nucl. Med., 2010, 51 (7), 1059-1067.
226. Wild, D.; Macke, H.; Christ, E.; Gloor, B.; Reubi, J. C. Glucagonlike peptide 1-receptor scans to localize occult insulinomas. N. Engl. J. Med., 2008, 359 (7), 766-768.
227. Christ, E.; Wild, D.; Forrer, F.; Brandle, M.; Sahli, R.; Clerici, T.; Gloor, B.; Martius, F.; Maecke, H.; Reubi, J. C. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab., 2009, 94 (11), 4398-4405.
228. Korner, M.; Waser, B.; Reubi, J. C. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab. Invest., 2004, 84 (1), 71-80.
229. Korner, M.; Waser, B.; Reubi, J. C. Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. Int. J. Cancer, 2005, 115 (5), 734-741.
230. Korner, M.; Waser, B.; Reubi, J. C. High expression of neuropeptide Y1 receptors in Ewing sarcoma tumors. Clinical Cancer Research, 2008, 14 (16), 5043-5049.
231. Korner, M.; Reubi, J. C. NPY receptors in human cancer: A review of current knowledge. Peptides, 2007, 28 (2), 419-425.
232. Khan, I. U.; Zwanziger, D.; Bohme, I.; Javed, M.; Naseer, H.; Hyder, S. W.; Beck-Sickinger, A. G. Breast-cancer diagnosis by Neuropeptide Y analogues: from synthesis to clinical application. Angew. Chem.-Int. Edit., 2010, 49 (6), 1155-1158.
233. Quinn, T.; Zhang, X.; Miao, Y. Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. G. Ital. Dermatol. Venereol., 2010, 145 (2), 245-258.
234. Wraight, E. P.; Bard, D. R.; Maughan, T. S.; Knight, C. G.; Pagethomas, D. P. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant-melanoma. Br. J. Radiol., 1992, 65 (770), 112-118.
235. Miao, Y.; Gallazzi, F.; Guo, H.; Quinn, T. P. In-111-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjugate Chemistry, 2008, 19 (2), 539-547.
236. Kersemans, V.; Kersemans, K.; Cornelissen, B. Cell penetrating peptides for in vivo molecular imaging applications. Current Pharmaceutical Design, 2008, 14 (24), 2415-2427.
237. Josephson, L.; Tung, C. H.; Moore, A.; Weissleder, R. Highefficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjugate Chemistry, 1999, 10 (2), 186-191.
238. Zhao, M.; Kircher, M. F.; Josephson, L.; Weissleder, R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjugate Chemistry, 2002, 13 (4), 840-844.
239. Dodd, C. H.; Hsu, H. C.; Chu, W. J.; Yang, P. G.; Zhang, H. G.; Mountz, J. D.; Zinn, K.; Forder, J.; Josephson, L.; Weissleder, R.; Mountz, J. M. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivatorpeptide-derived superparamagnetic nanoparticles. J. Immunol. Methods, 2001, 256 (1-2), 89-105.
240. Ruan, G.; Agrawal, A.; Marcus, A. I.; Nie, S. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J. Am. Chem. Soc., 2007, 129 (47), 14759-14766.
241. Kuil, J.; Velders, A. H.; van Leeuwen, F. W. B. Multimodal tumortargeting peptides functionalized with both a radio-and a fluorescent label. Bioconjugate Chemistry, 2010, 21 (10), 1709-1719.
242. Delbeke, D.; Coleman, R. E.; Guiberteau, M. J.; Brown, M. L.; Royal, H. D.; Siegel, B. A.; Townsend, D. W.; Berland, L. L.; Parker, J. A.; Hubner, K.; Stabin, M. G.; Zubal, G.; Kachelriess, M.; Cronin, V.; Holbrook, S. Procedure guideline for tumor imaging with F-18-FDG PET/CT 1.0. J. Nucl. Med., 2006, 47 (5), 885-895.
243. Delbeke, D.; Coleman, R. E.; Guiberteau, M. J.; Brown, M. L.; Royal, H. D.; Siegel, B. A.; Townsend, D. W.; Berland, L. L.; Parker, J. A.; Zubal, G.; Cronin, V. Procedure guideline for SPECT/CT imaging 1.0. J. Nucl. Med., 2006, 47 (7), 1227-1234.
244. O'Connor, M. K.; Kemp, B. J. Single-photon emission computed tomography/computed tomography: Basic instrumentation and innovations. Seminars in Nuclear Medicine, 2006, 36 (4), 258-266.
245. Garanger, E.; Boturyn, D.; Jin, Z. H.; Dumy, P.; Favrot, M. C.; Coll, J. L. New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. Molecular Therapy, 2005, 12 (6), 1168-1175.
246. Jennings, L. E.; Long, N. J. 'Two is better than one'-probes for dual-modality molecular imaging. Chem. Commun., 2009, (24), 3511-3524.
247. Houston, J. P.; Ke, S.; Wang, W.; Li, C.; Sevick-Muraca, E. M. Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumortargeting probe. J. Biomed. Opt., 2005, 10 (5), 11.
248. Li, C.; Wang, W.; Wu, Q. P.; Shi, K.; Houston, J.; Sevick-Muraca, E.; Dong, L.; Chow, D.; Charnsangavej, C.; Gelovani, J. G. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl. Med. Biol., 2006, 33 (3), 349-358.
249. Edwards, W. B.; Akers, W. J.; Ye, Y. P.; Cheney, P. P.; Bloch, S.; Xu, B. G.; Laforest, R.; Achilefu, S. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Molecular Imaging, 2009, 8 (2), 101-110.
250. Kimura, R. H.; Miao, Z.; Cheng, Z.; Gambhir, S. S.; Cochran, J. R. A dual-labeled Knottin peptide for PET and Near-Infrared fluorescence imaging of integrin expression in living subjects. Bioconjugate Chemistry, 2010, 21 (3), 436-444.
251. Cai, W. B.; Chen, X. Y. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med., 2008, 49, 113S-128S.
252. Cai, W. B.; Chen, K.; Li, Z. B.; Gambhir, S. S.; Chen, X. Y. Dualfunction probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med., 2007, 48 (11), 1862-1870.
253. Nahrendorf, M.; Keliher, E.; Marinelli, B.; Waterman, P.; Feruglio, P. F.; Fexon, L.; Pivovarov, M.; Swirski, F. K.; Pittet, M. J.; Vinegoni, C.; Weissleder, R. Hybrid PET-optical imaging using targeted probes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107 (17), 7910-7915.
254. Mulder, W. J. M.; Strijkers, G. J.; Habets, J. W.; Bleeker, E. J. W.; van der Schaft, D. W. J.; Storm, G.; Koning, G. A.; Griffioen, A. W.; Nicolay, K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Faseb J., 2005, 19 (12), 2008-+.
255. Mulder, W. J. M.; van der Schaft, D. W. J.; Hautvast, P. A. I.; Strijkers, G. J.; Koning, G. A.; Storm, G.; Mayo, K. H.; Griffioen, A. W.; Nicolay, K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. Faseb J., 2007, 21 (2), 378-383.
256. van Tilborg, G. A. F.; Mulder, W. J. M.; van der Schaft, D. W. J.; Reutelingsperger, C. P. M.; Griffioen, A. W.; Strijkers, G. J.; Nicolay, K. Improved magnetic resonance molecular imaging of tumor angiogenesis by Avidin-induced clearance of nonbound bimodal liposomes. Neoplasia, 2008, 10 (12), 1459-1469.
257. Montet, X.; Weissleder, R.; Josephson, L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjugate Chemistry, 2006, 17 (4), 905-911.
258. Boswell, C. A.; Eck, P. K.; Regino, C. A. S.; Bernardo, M.; Wong, K. J.; Milenic, D. E.; Choyke, P. L.; Brechbiel, M. W. Synthesis, characterization, and biological evaluation of integrin alpha(v)beta(3)-targeted PAMAM dendrimers. Molecular Pharmaceutics, 2008, 5 (4), 527-539.
259. Mulder, W. J. M.; Castermans, K.; van Beijnum, J. R.; Egbrink, M.; Chin, P. T. K.; Fayad, Z. A.; Lowik, C.; Kaijzel, E. L.; Que, I.; Storm, G.; Strijkers, G. J.; Griffioen, A. W.; Nicolay, K. Molecular imaging of tumor angiogenesis using alpha v beta 3-integrin targeted multimodal quantum dots. Angiogenesis, 2009, 12 (1), 17-24.
260. Lin, Y. H.; Dayananda, K.; Chen, C. Y.; Liu, G. C.; Luo, T. Y.; Hsu, H. S.; Wang, Y. M. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5. Bioorg. Med. Chem., 2011, 19 (3), 1085-1096.
261. McCann, C. M.; Waterman, P.; Figueiredo, J. L.; Aikawa, E.; Weissleder, R.; Chen, J. W. Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy. Neuroimage, 2009, 45 (2), 360-369.
262. Wang, L.; Xie, X.; Oh, J.-T.; Li, M.-L.; Ku, G.; Ke, S.; Similache, S.; Li, C.; Stoica, G. Combined photoacoustic and molecular fluorescence imaging in vivo. Conference proceedings:. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference, 2005, 1, 190-2.
263. Lee, H. Y.; Li, Z.; Chen, K.; Hsu, A. R.; Xu, C. J.; Xie, J.; Sun, S. H.; Chen, X. Y. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-Conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med., 2008, 49 (8), 1371-1379.
264. Yakovlev, V. V.; Noojin, G. D.; Denton, M. L.; Rockwell, B. A.; Thomas, R. J. Monitoring stimulated Raman scattering with photoacoustic detection. Optics Letters, 2011, 36 (7), 1233-1235.
265. De La Zerda, A.; Zavaleta, C.; Keren, S.; Vaithilingam, S.; Bodapati, S.; Liu, Z.; Levi, J.; Smith, B. R.; Ma, T. J.; Oralkan, O.; Cheng, Z.; Chen, X. Y.; Dai, H. J.; Khuri-Yakub, B. T.; Gambhir, S. S. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nature Nanotechnology, 2008, 3 (9), 557-562.
266. Liu, Z.; Cai, W. B.; He, L. N.; Nakayama, N.; Chen, K.; Sun, X. M.; Chen, X. Y.; Dai, H. J. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nature Nanotechnology, 2007, 2 (1), 47-52.
267. de la Zerda, A.; Liu, Z. A.; Bodapati, S.; Teed, R.; Vaithilingam, S.; Khuri-Yakub, B. T.; Chen, X. Y.; Dai, H. J.; Gambhir, S. S. Ultrahigh Sensitivity Carbon Nanotube Agents for Photoacoustic Molecular Imaging in Living Mice. Nano Letters, 2010, 10 (6), 2168-2172.
268. Stelter, L.; Pinkernelle, J. G.; Michel, R.; Schwartlander, R.; Raschzok, N.; Morgul, M. H.; Koch, M.; Denecke, T.; Ruf, J.; Baumler, H.; Jordan, A.; Hamm, B.; Sauer, I. M.; Teichgraber, U. Modification of aminosilanized superparamagnetic nanoparticles: Feasibility of multimodal detection using 3T MRI, small animal PET, and fluorescence imaging. Molecular Imaging and Biology, 2010, 12 (1), 25-34.
269. Ko, H. Y.; Choi, K. J.; Lee, C. H.; Kim, S. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alpha(v)beta(3) and tenascin-C proteins. Biomaterials, 2011, 32 (4), 1130-1138.
270. Bernard, B.; Capello, A.; van Hagen, M.; Breeman, W.; Srinivasan, A.; Schmidt, M.; Erion, J.; van Gameren, A.; Krenning, E.; de Jong, M. Radiolabeled RGD-DTPA-Tyr(3)-octreotate for receptortargeted radionuclide therapy. Cancer Biother. Radiopharm., 2004, 19 (2), 173-180.
271. Capello, A.; Krenning, E. P.; Bernard, B. F.; Breeman, W. A. P.; van Hagen, M. P.; de Jong, M. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J. Nucl. Med., 2004, 45 (10), 1716-1720.
272. Capello, A.; Krenning, E. P.; Bernard, B. F.; Breeman, W. A. P.; Erion, J. L.; de Jong, M. Anticancer activity of targeted proapoptotic peptides. J. Nucl. Med., 2006, 47 (1), 122-129.
273. Li, Z. B.; Wu, Z. H.; Chen, K.; Ryu, E. K.; Chen, X. Y. F-18-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med., 2008, 49 (3), 453-461.
274. Liu, Z. F.; Li, Z. B.; Cao, Q. Z.; Liu, S. L.; Wang, F.; Chen, X. Y. Small-animal PET of tumors with (64Cu)-labeled RGD-Bombesin heterodimer. J. Nucl. Med., 2009, 50 (7), 1168-1177.
275. Liu, Z. F.; Niu, G.; Wang, F.; Chen, X. Y. Ga-68-labeled NOTARGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36 (9), 1483-1494.
276. Liu, Z. F.; Yan, Y. J.; Chin, F. T.; Wang, F.; Chen, X. Y. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using F-18-labeled PEGylated RGD-Bombesin heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. J. Med. Chem., 2009, 52 (2), 425-432.
277. Yan, Y. J.; Chen, K.; Yang, M.; Sun, X. L.; Liu, S. L.; Chen, X. Y. A new (18)F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids, 2011, 41 (2), 439-447.
278. Liu, Z. F.; Yan, Y. J.; Liu, S. L.; Wang, F.; Chen, X. Y. F-18, Cu-64, and Ga-68 labeled RGD-Bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjugate Chemistry, 2009, 20 (5), 1016-1025.
279. Liu, Z. F.; Wang, F. Dual-targeted molecular probes for cancer imaging. Current Pharmaceutical Biotechnology, 2010, 11 (6), 610-619.
280. Santos-Cuevas, C. L.; Ferro-Flores, G.; de Murphy, C. A.; Ramirez, F. D.; Luna-Gutierrez, M. A.; Pedraza-Lopez, M.; Garcia-Becerra, R.; Ordaz-Rosado, D. Design, preparation, in vitro and in vivo evaluation of Tc-99m-N2S2-Tat(49-57)-bombesin: A targetspecific hybrid radiopharmaceutical. Int. J. Pharm., 2009, 375 (1-2), 75-83.
281. Santos-Cuevas, C. L.; Ferro-Flores, G.; Rojas-Calderon, E. L.; Garcia-Becerra, R.; Ordaz-Rosado, D.; de Murphy, C. A.; Pedraza-Lopez, M. Tc-99m-N2S2-Tat (49-57)-bombesin internalized in nuclei of prostate and breast cancer cells: kinetics, dosimetry and effect on cellular proliferation. Nucl. Med. Commun., 2011, 32 (4), 303-313.
282. Morales-Avila, E.; Ferro-Flores, G.; Ocampo-Garcia, B. E.; De Leon-Rodriguez, L. M.; Santos-Cuevas, C. L.; Garcia-Becerra, R.; Medina, L. A.; Gomez-Olivan, L. Multimeric system of Tc-99mlabeled gold nanoparticles conjugated to cRGDfK(C) for molecular imaging of tumor alpha(v)beta(3) expression. Bioconjugate Chemistry, 2011, 22 (5), 913-922.